Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XZP-5809-TT1 in T790M-positive NSCLC After EGFR-TKI Failure
NCT04622072Phase 1Terminated
- Sponsor
- Sihuan Pharmaceutical
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of xzp-5809 in non-small cell lung cancer (NSCLC), sponsored by Sihuan Pharmaceutical. Primary endpoints: Adverse Event, Objective Response Rate and 2 more. Started Nov 2020; status: terminated.
02
Drugs
xzp-5809
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04622072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622072.